ASIT biotech Announces the Publication of Its 2018 Annual Financial Report
13 Mai 2019 - 6:00PM
Business Wire
Regulatory News:
ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT -
BE0974289218), a Belgian clinical-stage biopharmaceutical
company focused on the research, development and future
commercialization of breakthrough immunotherapy products for the
treatment of allergies, today announces the publication of its 2018
annual financial report.
The document can be downloaded on the website of the Company
under the section Investors / Documentation / Financial
reports.
***
About ASIT biotechASIT biotech is a Belgian clinical
stage biopharmaceutical company focused on the development and
future commercialization of a range of breakthrough immunotherapy
products for the treatment of allergies. Thanks to its innovative
ASIT+™ technology platform, ASIT biotech is currently the only
developer of allergy immunotherapy (AIT) product candidates
consisting of a unique mixture of highly purified natural allergen
fragments in an optimal size selection. This innovation results in
a short treatment, expected to improve patient compliance and
real-life effectiveness. ASIT biotech’s product pipeline contains
three novel ASIT+™ product candidates targeting respiratory
allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™
- in ongoing phase III - and house dust mite: hdm-ASIT+™), and food
allergies (peanut allergy: pnt-ASIT+™) that could significantly
expand the current immunotherapy market. The Company believes that
its innovative ASIT+™ platform is flexible and would be applicable
across a range of allergies.
ASIT biotech has a headcount of 26 staff members, at its
headquarters in Brussels and its facilities in Liège, Belgium.
Further information can be found at www.asitbiotech.com.
Forward-looking statementsAll statements in this
announcement that do not relate to historical facts and events are
“forward-looking statements”. In some cases, these forward-looking
statements can be identified by the use of forward-looking
terminology, including the words “believes,” “estimates,”
“anticipates,” “expects,” “intends,” “may,” “will,” “plans,”
“continue,” “ongoing,” “potential,” “predict,” “project,” “target,”
“seek” or “should” or, in each case, their negative or other
variations or comparable terminology or by discussions of
strategies, plans, objectives, targets, goals, future events or
intentions. Forward-looking statements include statements regarding
the Company’s intentions, beliefs or current expectations. By their
nature, forward-looking statements involve known and unknown risks
and uncertainties because they relate to events and depend on
circumstances that may or may not occur in the future.
Forward-looking statements are not guarantees of future
performance. Given these risks and uncertainties, you should not
rely on forward-looking statements as a prediction of actual
results. Any forward-looking statements are made only as of the
date of this announcement and, without prejudice to the Company’s
obligations under applicable law in relation to disclosure and
ongoing information, the Company does not intend, and does not
assume any obligation, to update the forward-looking statements set
forth in this announcement.
Legal noticeThis announcement does not constitute, or
form part of, an offer or invitation to sell or issue, or any
solicitation of an offer to purchase or subscribe for shares of
ASIT biotech SA (the “Company” and the “Shares”). Any purchase of,
subscription for or application for, Shares to be issued in
connection with the intended offering should only be made on the
basis of information contained in the prospectus and any
supplements thereto, as the case may be. This announcement does not
constitute a prospectus and the information contained herein is for
information purposes only and does not purport to be full or
complete. Investors should not subscribe for any Shares except on
the basis of the information contained in the prospectus that the
Company expects to publish after its approval by the Belgian
Financial Services and Markets Authority, and which can then be
obtained at the Company’s registered office and on
www.asitbiotech.com.
This announcement is not for distribution, directly or
indirectly, in or into the United States or to any U.S. person
within the meaning of the U.S. Securities Act of 1933, as amended
(the “Securities Act”). The Shares have not been and will not be
registered under the Securities Act and may not be offered or sold
in the United States, except pursuant to an exemption from the
registration requirements of the Securities Act. The Company has
not registered, and does not intend to register, any portion of the
intended offering of Shares in the United States, and does not
intend to conduct a public offering of Shares in the United
States.
This announcement and the information contained herein are not
for publication, distribution or release in or into the United
States, Australia, Canada, Japan or any jurisdiction where to do so
would constitute a violation of the relevant laws of such
jurisdiction.
The Company is responsible for the information contained in this
press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190513005582/en/
CompanyMichel Baijot, CEOASIT biotechTel.: +32 2 264 03
90investors@asitbiotech.com
Media and Investor Relations - FranceNewCapDusan
Oresansky / Pierre LaurentTel.: +33 1 44 71 94
92asitbiotech@newcap.eu
Media Relations - BelgiumLaure-Eve MonfortTel.: +32 2 290
90 93monfort@comfi.be